| Dr Steven C Borene, MD | |
|
515 22nd Ave, Monroe, WI 53566-1569 | |
| (608) 324-2000 | |
| Not Available |
| Full Name | Dr Steven C Borene |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 24 Years |
| Location | 515 22nd Ave, Monroe, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851345383 | NPI | - | NPPES |
| 37146 | Other | IA | BLUE CROSS |
| 0445635 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 49904 (Wisconsin) | Secondary |
| 207L00000X | Anesthesiology | 35517 (Iowa) | Secondary |
| 207L00000X | Anesthesiology | 49904-20 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aurora St Lukes Medical Center | Milwaukee, WI | Hospital |
| Ascension Se Wisconsin Hospital - St Joseph Campus | Milwaukee, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
| Wheaton Franciscan Medical Group Inc | 8628980943 | 594 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.
Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.
› Verified 2 days ago
| Entity Name | The Monroe Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386720548 PECOS PAC ID: 3072425495 Enrollment ID: O20031104000392 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.
Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.
› Verified 2 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.
Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.
› Verified 2 days ago
| Entity Name | Gundersen Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851343115 PECOS PAC ID: 9638082779 Enrollment ID: O20031106000139 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.
Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.
› Verified 2 days ago
| Entity Name | The Medical College Of Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.
Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.
› Verified 2 days ago
| Entity Name | Gundersen Lutheran Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376593442 PECOS PAC ID: 2163331414 Enrollment ID: O20130619000254 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.
Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.
› Verified 2 days ago
| Entity Name | Ascension Medical Group-southeast Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194473066 PECOS PAC ID: 8628980943 Enrollment ID: O20220620000485 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.
Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven C Borene, MD 515 22nd Ave, Monroe, WI 53566-1569 Ph: (608) 324-2000 | Dr Steven C Borene, MD 515 22nd Ave, Monroe, WI 53566-1569 Ph: (608) 324-2000 |
News Archive
Yaupon Therapeutics, a privately held specialty pharmaceutical company, today announced positive top-line results from the pivotal multi-center study of its lead product candidate, a proprietary topical mechlorethamine gel for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages I-IIa). The top-line data show that the study, which was conducted under a Special Protocol Assessment (SPA), achieved its primary and secondary endpoints.
Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.
Because proton therapy can be targeted much more precisely, it should minimize any damage to sensitive nerves and tissue around the prostate.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Spyros Kalams will provide an update of interim immune responses and safety results from the HVTN 080 Phase I clinical study of Inovio's PENNVAX-B HIV DNA vaccine in a preventive setting.
› Verified 2 days ago
Mr. Dana Decker Doll, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 515 22nd Ave, Monroe, WI 53566 Phone: 608-324-1454 | |
Kishor G Rana, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 515 22nd Ave, Monroe, WI 53566 Phone: 608-324-1000 | |
Ms. Christine E Hunsicker, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 515 22nd Ave, Anesthesiology, Monroe, WI 53566 Phone: 608-324-2000 | |
Mr. Martin L Arnold, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 515 22nd Ave, Monroe, WI 53566 Phone: 608-324-1000 | |
Dr. Mark W. Collar, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 515 22nd Ave, Monroe Clinic, Monroe, WI 53566 Phone: 608-324-2222 | |
Meghan C. Oujiri, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 515 22nd Ave, Monroe, WI 53566 Phone: 608-324-1305 Fax: 608-324-1246 |